Two injections of interferon-α could trigger the development of rheumatoid arthritis

Sirs,

Various autoimmune diseases including rheumatoid arthritis (RA) have been admittedly manifested after interferon (IFN)-α therapy against malignancies or viral hepatitis (1-3). The manifestation of RA from the therapy takes usually several months (4-7). Here we present a case of RA which has been precipitated after only 2 injections of IFN-α and discussed the significance of IFN-α as a trigger of immune abnormalities in the pathogenesis of RA.

Eighteen months earlier, a 50-year-old woman began to feel polyarthralgia in the metacarpal, proximal interphalangeal (PIP) and wrist joints and the serum rheumatoid factor (RF) was positive, although her symptoms were self-limiting. Three months before admission, because of the renal cell carcinoma, she was administered after nephrectomy with 3 x 10^6 units of IFN-α (Sumiferon, Sumitomo Pharmaceutics, Japan), followed by spike fever and polyarthralgia, and the former subsided with aspirin. Because polyarthralgia gradually worsened and morning stiffness of the fingers was noted after the second injection performed a week later, IFN-α was discontinued, and she was referred to our clinic. There were no abnormalities except for swelling of bilateral PIP and wrist joints. The erythrocyte sedimentation rate (ESR) was 38 mm/h and CRP was 1.0 mg/dl. The titer of the serum RF determined by RF-III ELISA kit (Eiken Chemical Co., Japan) was 30 IU/ml (N < 10 IU/ml) and increased to 56 IU/ml 2 weeks later. The serum anti-nuclear antibody and antibodies to various viruses including EB virus, hepatitis C virus or human T-cell leukemia virus-1 was negative. An X-ray of the hand disclosed no osteoporosis or bone erosions. Under the diagnosis of RA according to the criteria by American Rheumatism Association (8), bucillamine, an anti-rheumatic agent, was administered. Ten weeks later, polyarthralgia, swelling of the joints and morning stiffness became mild, as the titer of RF decreased to 7 to 19 IU/ml. There has been no recurrence of renal cell carcinoma for more than 9 months.

In this case, polyarthritis flared up, persisted for over 8 weeks with elevated RF titers after only 2 injections of IFN-α and became mild 10 weeks after discontinuation of IFN-α, while the effect of bucillamine was uncertain. On the other hand, her clinical course was not compatible with paraneoplastic syndrome or viral infections. Although coincidence of the manifestation of RA and IFN-α therapy could not be excluded, from difference of the clinical course between 15 months before and 9 months after the IFN-α therapy, it is likely that the administration of IFN-α might have triggered off the manifestation of RA.

IFN-α is known to activate macrophages to secrete tumor necrosis factor (TNF)-α or interleukin (IL)-1, and to show chemotactic activity for neutrophils. Furthermore, it has been reported that IFN-α up-regulates expression of major histocompatibility complex antigens on antigen-presenting cells (9). Among proinflammatory cytokines, TNF-α and IL-1 have been thought important because they induce production of other proinflammatory cytokines or prostaglandins, proliferation of fibroblasts or activation of osteoclasts, all of which are involved in the pathogenesis of RA. Therefore, chronic stimulation with IFN-α is likely to be associated with exacerbation of RA. In general, 3 to 10 x 10^6 units/day of IFN-α is administered daily or once a week for several months. Time to onset of different autoimmune diseases after initiation of the IFN-α therapy has varied from 3 to 5 months in RA (2,10). From this case, very minor doses of IFN-α could be enough to trigger a vicious cycle of immune abnormalities associated with the pathogenesis of RA. Particularly, when the patients have a history of rheumatoid arthritis or arthralgia, IFN-α should be used carefully under consideration of the manifestation of RA.

M. FUNAUCHI, *MD* M. OHNO, *MD*
Y. NOZAKI K. KINOSHITA, *MD*
M. SUGIYAMA, *MD* A. KANAMARU, *MD*

Division of Hematology, Nephrology and Rheumatology, Kinki University School of Medicine, Osaka, Japan.
Address correspondence and reprint requests to: Masanori Funauchi, Division of Hematology, Nephrology and Rheumatology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Osaka, Japan.
E-mail: funauchi@med.kindai.ac.jp

References

1. PITTAU E, BOGLIOLO A, TINTI A *et al.*: Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. *Clin Exp Rheumatol* 1997; 15: 415-9.
2. OKANOUE T, SAKAMOTO S, ITOH Y *et al.*: Side effect of high-dose interferon therapy for chronic hepatitis C. *J Hepatol* 1996; 25: 283-91.
3. IOANNOU Y, ISENBERG DA: Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. *Arthritis Rheum* 2000; 43: 1431-42.
4. NADIR F, FAGIUOLI S, WRIGHT HI *et al.*: Rheumatoid arthritis: A complication of interferon therapy. *J Okla State Med Assoc* 1994; 87: 228-30.
5. PASSOS DE SOUZA E, EVANGELISTA SEGUNDO PT, JOSE FF, LEMAIRE D, SANTIAGO M: Rheumatoid arthritis induced by alpha-interferon therapy. *Clin Rheumatol* 2001; 20: 297-9.
6. JOHNSON DM, HAYAT SQ, BURTON GV: Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma. *J Rheumatol* 1999; 26: 1009-10.
7. NESHER G, RUCHLEMER R: Alpha-interferon-induced arthritis: Clinical presentation treatment, and prevention. *Semin Arthritis Rheum* 1998; 27: 360-5.
8. ARNETT FC, EDWOTHY SM, BLOCH DA *et al.*: The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 315-34.
9. DE MAEYAR E, DE MAEYAR-GUIGNARD J: Type I interferon. *Int Rev Immunol* 1998; 17: 53-73.
10. KOTTER L, MULLER CA, EINSELE H, MOHREN M, KANZ L: Interferon-α -associated polyarthritis. Possible induction arthritis by interferon-α: Two case report and review of the literature. *J Rheumatol* 1999; 58: 185-95.

No association of interleukin-4 gene polymorphisms in Chinese patients with rheumatoid arthritis in Taiwan

Sirs,

The genetic background of RA is still mostly unknown. Only a few cytokine gene polymorphisms (TNFα, IL-6, and IL-1α) have been studied. To date, genetic studies of multifactorial diseases have been difficult due to uncertainty surrounding the presence of a polygenic trait. In the present study, we chose 2 gene polymorphisms (IL-4 promoter and IL-4 intron 3) to screen candidate genes located outside the MHC. The gene for IL-4 has been mapped to the q am (q23-31) of chromosome 5 (1), in a cluster of cytokine genes (IL-3, IL-5, IL-9, IL-13, IL-15, GM-CSF, and interferon regulatory factor). The polymorphism is a C to T change at position –590 counting from the first ATG codon (2). The polymorphism is upstream of all the previously described control elements of IL-4. Another polymorphism has been located in the third intron, and is composed of a variable number of tandem repeats (VNTR) of a 70-bp sequence (3).

The purpose of this study was to examine whether Interleukin-4 gene polymorphism are markers of susceptibility of rheumatoid arthritis (RA) in Taiwan. The study included 104 patients with RA (4) and 103 unrelated, healthy individuals who were living in the middle of Taiwan were used as controls. From genomic DNA, 2 polymorphisms in genes for IL-4 (IL-4 intron 3 and IL-4 promoter) were typed. Allelic frequencies and carriage rates were compared be-